AbbVie’s 400% return over 10 years surpasses the S&P 500, driven by Humira successors and Allergan acquisition growth.
AbbVie (NYSE:ABBV) delivered a 400% return over the past decade, turning a $1,000 investment into $5,000, while its dividend tripled from $0.57 to $1.73 per share. The stock outperformed the S&P 500 by 139 percentage points, though it lagged broader market gains in the past year.
Humira, once the company’s $21 billion peak revenue driver, saw sales plummet to $688 million in Q1 2026 after biosimilar competition emerged. Skyrizi and Rinvoq, however, generated $4.483 billion and $2.119 billion in Q1 2026, respectively, offsetting the decline. The $63 billion Allergan acquisition in 2020 added Botox and Juvederm, contributing to a 26% growth in neuroscience last quarter.
Full-year 2025 revenue reached $61.16 billion, with management raising 2026 adjusted EPS guidance to $14.08-$14.28. Despite strong long-term performance, AbbVie underperformed the S&P 500 in the past year, with a 18.97% return versus the index’s 28.15%.